VEGFA and neoplasm: Although controversial, pre-clinical studies in mice have raised concerns that, sunitinib, a multi-targeted TKI which inhibits VEGF signalling may lead to paradoxical enhancement of tumor metastatic growth in some tumor models (Iacovelli et al., 2012).